newsfilter
← Latest News
GlobeNewswire·

SAB Biotherapeutics Announces Departure of Chief Financial Officer

MIAMI, May 30, 2024 (GLOBE NEWSWIRE) -- SAB Biotherapeutics (NASDAQ:SABS) (the "Company" or "SAB"), a clinical-stage biopharmaceutical company with a novel immunotherapy platform developing a human anti-thymocyte